• CARD8 Inflammasome-Mediated Pyroptosis in Human T Cells Reve

  2026-05-11

  This study uncovers that inhibition of dipeptidyl peptidases using Val-boroPro, also known as Talabostat mesylate (PT-100), activates the CARD8 inflammasome and induces pyroptotic cell death in resting human T cells. The findings extend the relevance of inflammasome signaling beyond myeloid cells and reshape our understanding of T cell death and immune modulation in disease.

• IL-17A as a Prognostic Biomarker in GBS-Colonized Pregnancie

  2026-05-11

  This study identifies low maternal IL-17A as a predictive biomarker for neonatal risk in pregnancies complicated by Group B Streptococcus (GBS) colonization. By integrating clinical cohort data with ex vivo immune stimulation, the research clarifies how impaired TLR1/2-driven cytokine responses may underlie vertical transmission risk.

• Exemestane: Steroidal Aromatase Inhibitor Workflows in Resea

  2026-05-10

  Leverage Exemestane’s irreversible, selective inhibition for robust estrogen biosynthesis studies in breast cancer research. This guide details optimized experimental workflows, troubleshooting strategies, and evidence-driven protocol parameters to maximize reliability and reproducibility in hormone-dependent models.

• Palonosetron in CINV Prevention: Insights for Colorectal Can

  2026-05-09

  This review dissects the pharmacological innovation and clinical efficacy of palonosetron hydrochloride in the prevention of chemotherapy-induced nausea and vomiting (CINV), with an emphasis on mechanistic distinctions from earlier 5-HT3 antagonists. Its findings are contextualized for researchers employing DNA-damaging agents such as Irinotecan in preclinical colorectal cancer models.

• Epinephrine Bitartrate: Workflow-Driven Protocols & Troubles

  2026-05-08

  Epinephrine Bitartrate (SKU B1358) from APExBIO delivers reproducible, high-impact results across cardiovascular, neurobiology, and cell signaling research. This guide translates bench-validated workflows, real-world troubleshooting, and cutting-edge trial insights into actionable protocols for adrenergic receptor agonist applications.

• Aconitase Activity Colorimetric Assay Kit: Metabolic Precisi

  2026-05-08

  Discover how the Aconitase Activity Colorimetric Assay Kit enables precise detection of mitochondrial aconitase activity, with a unique focus on metabolic flexibility and immunometabolic research. Explore advanced applications and essential protocol parameters for robust oxidative damage measurement.

• Probenecid: Mechanistic Leverage for Translational Innovatio

  2026-05-07

  This article offers a strategic, mechanistic, and workflow-focused exploration of Probenecid (4-(dipropylsulfamoyl)benzoic acid) as a multidimensional research tool. Building on recent immunometabolic findings and established roles in multidrug resistance and neuroprotection, we synthesize actionable guidance for translational researchers seeking to overcome key experimental bottlenecks in oncology and neuroinflammation. The discussion integrates referenced literature, benchmarks APExBIO's Probenecid against the competitive landscape, and highlights next-generation opportunities in workflow optimization and mechanistic exploration.

• ABT-263 (Navitoclax): Precision Tools for Translational Onco

  2026-05-07

  Explore how ABT-263 (Navitoclax) is reshaping translational cancer research by enabling strategic, mechanism-driven approaches to apoptosis and senescence targeting. Drawing on recent melanoma studies and validated laboratory workflows, this article delivers actionable guidance and competitive insight for researchers leveraging Bcl-2 family inhibition to overcome resistance and achieve reproducible, clinically relevant results.

• Smoothened Agonist (SAG): Precision Tool for Tumorigenesis a

  2026-05-06

  Explore how Smoothened Agonist (SAG) enables precision Hedgehog pathway activation for tumorigenesis studies and developmental models. Discover advanced protocols, comparative insights, and practical guidance beyond standard neuroprotection research.

• Etoposide (VP-16): Optimizing DNA Damage and Apoptosis Assay

  2026-05-06

  Etoposide (VP-16) empowers cancer research through precise induction of DNA double-strand breaks and apoptosis in in vitro and in vivo models. This guide translates recent mechanistic advances—such as lncRNA-modulated chemosensitization—into actionable workflows, troubleshooting, and performance benchmarks for DNA damage assays and cancer chemotherapy research.

• Ridaforolimus (Deforolimus) in Cancer Research: Protocols &

  2026-05-05

  Ridaforolimus (Deforolimus, MK-8669) is a highly selective mTOR inhibitor with nanomolar potency, enabling reproducible inhibition of cancer cell proliferation and angiogenesis. This article explores advanced workflow optimizations, troubleshooting strategies, and practical insights for integrating Ridaforolimus into apoptosis and anti-angiogenesis assays across diverse cancer models.

• 3D Organoid-Fibroblast Models Reveal PDAC Chemoresistance Me

  2026-05-05

  Schuth et al. present a patient-specific 3D co-culture model incorporating pancreatic tumor organoids and matched cancer-associated fibroblasts (CAFs), directly demonstrating how stromal components drive chemoresistance in pancreatic ductal adenocarcinoma (PDAC). This study advances mechanistic understanding of tumor-stroma interactions and informs the development of more predictive preclinical drug screening systems.

• Dendritic Cell-Mediated Amikacin Delivery Into Mycobacterial

  2026-05-04

  This study demonstrates a targeted drug delivery strategy using dendritic cells (DCs) to transport amikacin directly into granulomas formed during Mycobacterium avium infection. The approach enhances local antibiotic concentration while minimizing systemic exposure, providing a novel avenue for antibiotic resistance research and mycobacterial infection management.

• PP 1 Src Family Tyrosine Kinase Inhibitor: Advanced Workflow

  2026-05-04

  PP 1 stands out as a highly selective Src family tyrosine kinase inhibitor, enabling researchers to dissect complex oncogenic and immune signaling with nanomolar precision. This article delivers actionable protocols, troubleshooting insights, and translational use-cases that set PP 1 apart for robust, reproducible studies in cancer biology and immunomodulation.

• Synergistic OXPHOS Disruption: LRPPRC Inhibition & Dasatinib

  2026-05-03

  This study demonstrates a novel combination strategy for cancer therapy by pairing LRPPRC inhibition with dasatinib to achieve dual-genome disruption of oxidative phosphorylation (OXPHOS). Mechanistic insights reveal that this approach selectively impairs both nuclear- and mitochondrial-encoded OXPHOS genes, providing a strong rationale for tumor-selective metabolic targeting.

16933 records 4/1129 page Previous Next 12345 下5页 Last page